GlassScriptPhysician profile
Robert Miller Buchanan
NPI 1235540824
$1,689.20
in general payments reported to CMS, 2019-2025
23 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.69 · 2023: $359 · 2024: $1,044 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.95 | 2023-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $240.36 | 2023-2025 | |
| Novo Nordisk INC | $210.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $155.06 | 2023-2024 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $99.22 | 2023-2024 | |
| Amgen INC. | $95.55 | 2020-2024 | Repatha, Otezla |
| Dexcom, INC. | $81.74 | 2024 | Dexcom G6 Transmitter |
| Insightec,INC | $64.28 | 2024 | Exablate |
| Exact Sciences Corporation | $62.65 | 2023-2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $45.68 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $37.12 | 2023-2024 | Trintellix |
| Inspire Medical Systems, INC. | $35.59 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.23 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $31.29 | 2024 | Capvaxive |
| Glaxosmithkline, LLC. | $29.59 | 2024 | Shingrix, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.68 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $26.68 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $25.02 | 2024 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $19.24 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $16.74 | 2025 | Symbravo |
| Actelion Pharmaceuticals US, INC. | $15.19 | 2024 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $14.25 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.